Zdrowie i gospodarka · 05/11/1998

FDA Issues Interim Rule on Abbreviated New Drug Application Approval Dates

The US Food and Drug Administration (FDA) has announced an interim rule that eliminates the need for abbreviated new drug application (ANDA) applicants to successfully defend a patent infringement lawsuit to qualify for 180 days of marketing exclusivity, effective immediately.